we care
«The Company of Decade - the Russian pharmaceutical products manufacturer»

Press releases
Pharmstandard and Ferring announce collaboration to localize full-cycle manufacturing of innovative obstetrical and gynaecological pharmaceuticals in Russia

Moscow, August 26, 2016 - Global biopharmaceutical company Ferring Pharmaceuticals and Pharmstandard JSC, Russia’s leading pharmaceutical company, have announced a strategic partnership for full-cycle manufacturing of Tractocile (INN atosiban) and Pabal (INN carbetocin) for preventing premature birth and postpartum hemorrhage.

From 2016-2018, high-tech full cycle aseptic manufacturing of injectable drugs will be launched at the Pharmstandard-UfaVITA OJSC plant in Ufa. The plant will produce about 40,000 packs of Tractocile and 15,000 packs of Pabal annually, completely meeting the demand for these products in Russia and the EAEU. Production will be carried out in accordance with national and European good manufacturing practice (GMP), which in future will make it possible to export production to other countries.

In Russia, reducing infant and maternal mortality is a priority for the Russian Government. Premature birth is a significant factor in infant mortality. The percentage of premature newborns accounts for up to 70% of early neonatal mortality and up to 75% of infant mortality. Tractocile (atosiban) has been successfully used for over 15 years across the world to maintain pregnancy.

According to the World Health Organization, each year about 140,000 women die from postpartum hemorrhage, which accounts for 25-33% of all maternal mortality cases. Pabal (carbetocin) helps to prevent postpartum hemorrhage.

In Russia, Tractocile (atosiban) and Pabal (carbetocin) have been included on the EDL list, as well as in all federal standards of specialized medical care and clinical guidelines in obstetrics since 2015.

Local full-cycle manufacturing will increase the rate of drug delivery and availability for providing modern healthcare services to pregnant women and newborns.

"Ferring is actively contributing in public policies related to improving demographic indicators in Russia. The joint project with Pharmstandard to localize production of innovative drugs for the treatment of preterm birth and prevention of postpartum hemorrhage will enhance the availability of healthcare for pregnant women in Russia, helping to save both their lives and the lives of their babies. In addition, our cooperation will be an important contribution in implementing the Pharma 2020 program aimed at developing the pharmaceutical industry in Russia," says Kirill Litovchenko, General Manager of Ferring Pharmaceuticals in Russia.

"Establishing partnerships with foreign pharmaceutical companies in the field of localization is one of the key elements of our strategy, which fits well into the public import substitution policy and Pharma 2020 strategy. We are pleased to launch a joint project with Ferring – given the high level of expertise and the availability of innovative pharmaceuticals, together we can offer new treatment opportunities to both Russian obstetricians and patients in this important area of women’s health," said Grigory Potapov, CEO of Pharmstandard JSC.

About Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

To learn more about Ferring or its products please visit www.ferring.com

About Pharmstandard JSC

Pharmstandard JSC, Russia’s leading pharmaceutical company, develops and manufactures high-quality modern pharmaceutical products, which meet the requirements of the healthcare system and the expectations of patients.

The most popular Pharmstandard products today are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphoglive®, Amixin®, Afobazol®, Rastan® and Biosulin®. The Company manufactures more than 250 pharmaceutical products including drugs for treatment of cardio-vascular diseases, diabetes, growth hormone deficiency, gastroenterological, neurological, and contagious diseases, metabolic disorders, cancer and other illnesses. More than 120 Pharmstandard products (taking into account all forms and dosages) are included on the list of Vital and Essential Pharmaceuticals.

All of the Company’s production facilities fully comply with Russian national standards, while 6 production lines at JSC Pharmstandard-Leksredstva have already received certificates of compliance with the EU GMP standards. All plants are to have been converted to European GMP standards by 2014, according to the schedule approved by Company’s management.



For more information please contact:

Julia Bakaeva

Communications and Digital Media Manager, Ferring Pharmaceuticals

Email: Julia.bakaeva@ferring.com

Tel: +7 (495) 287-03-43

Mob: +7 (916) 940-30-14


Alexey Chernushkin

Adviser for investments of General Manager of Pharmstandard JSC

Email: Ir@pharmstd.ru

Tel: + 7 (495) 970-00-30

Back Home Print
Company profile Company presentations Press releases Financial reports Annual reports Investor tools Investor calendar Analyst Coverage
Corporate film
Markets information WAP version
Delayed according to exchanges regulations. RUSTOCKS.com
Company profile Company presentations Press releases Financial reports Annual reports Investor tools Investor calendar Analyst Coverage
© 2007–2013 All rights reserved.
Terms of use www.pharmstd.com